The great obstetrical syndromes and the placenta

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Reproductive Biology

Background:

• The great obstetrical syndromes (GOS) encompass pre-eclampsia, preterm birth, abruption, fetal growth restriction, and stillbirth.
• Historically viewed as distinct, GOS share a common origin in placental development issues.
• Failure of deep placentation by 10-18 weeks gestation is a key factor in GOS pathogenesis.

Purpose of the Study:

• To explore the common pathophysiology underlying the great obstetrical syndromes.
• To investigate the role of maternal inflammation and thrombosis in GOS.
• To evaluate the potential of low-dose aspirin and other agents in preventing GOS.

Main Methods:

• Review of existing literature on placental development and GOS.
• Analysis of mechanisms linking maternal inflammation and thrombosis to GOS.
• Identification of candidate medications for GOS prevention.

Main Results:

• Failure of deep placentation, linked to maternal inflammation and thrombosis, is central to GOS.
• Early initiation of low-dose aspirin, targeting COX-1 and COX-2, may prevent all GOS components.
• Several other compounds, including hydroxychloroquine, metformin, and pravastatin, show potential for GOS prevention.

Conclusions:

• Maternal inflammation and thrombosis are key mechanisms in the pathogenesis of great obstetrical syndromes.
• Early low-dose aspirin intervention shows promise in preventing a spectrum of pregnancy complications.
• Further research is warranted to optimize aspirin dosage and explore novel therapeutic agents for GOS prevention.